| Date | Title | Description |
| 14.05.2024 | Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics | Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics
Industry veteran brings expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development
SOUT... |
| 12.05.2023 | Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights | Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors
Expanded clinical manufacturing capacity through successful technology transfer of CT-0508
Closed mer... |
| 05.05.2023 | Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023 | PHILADELPHIA, May 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. CARM ("Carisma"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company wi... |
| 05.04.2023 | Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights | Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol “CARM”
Cash position as of the closing of the merger with Sesen Bio provides anticipated operating runway through 2024
PHILADELPHIA, April 4, 2023 /PRNewswir... |
| 08.03.2023 | Carisma Therapeutics Closes Merger with Sesen Bio | Shares of Carisma to commence trading on Nasdaq under new ticker symbol “CARM” on March 8, 2023
Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carism... |
| 03.03.2023 | Sesen Bio Stockholders Approve Merger with Carisma Therapeutics | Declares Special Dividend in the Aggregate of $75 Million
Approximately 88% Voted in Favor of the Merger at the Special Meeting
Merger on Track to Close on March 7, 2023
CAMBRIDGE, Mass. — March 2, 2023 — Sesen Bio, Inc. (Nasdaq: SESN) (... |
| 16.02.2023 | Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger | Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Contingent Value Right for Vicineum to March 31, 2027
Bradley L. Radoff and Michael Torok to Vote Shares in Support of Transaction
Michael Torok t... |
| 09.02.2023 | Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board | PHILADELPHIA, Feb. 7, 2023 /PRNewswire/ — Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the appointment of Lin Guey, PhD to the company’s Sc... |
| 02.02.2023 | Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board | Expansion of Scientific Advisory Board provides additional expertise in development capabilities
PHILADELPHIA – January 31, 2023 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing ... |
| 03.01.2023 | Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger | Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
Sesen Bio Stockholders Expected to Receive Approximately $70 Million Special Cash Dividend,
an Increase fr... |
| 22.09.2022 | Sesen Bio and Carisma Therapeutics Announce Merger Agreement | Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other
serious disorders
Combined company expected to have approximately $180 million of cash, cash e... |
| 11.01.2022 | Moderna and Carisma establish collaboration to develop in vivo engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology | Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that the two companies ... |
| 09.04.2021 | CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting | |
| 18.03.2021 | CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans | |
| 02.03.2021 | CARISMA Therapeutics Inks $59M Series B |
PHILADELPHIA, PA, CARISMA Therapeutics added $12M to its Series B.
>> Click here for more funding data on CARISMA Therapeutics
>> To export CARISMA Therapeutics funding data to PDF and Excel, click here
CARISMA Therapeuti... |
| 01.03.2021 | Daily funding roundup - March 1st, 2021 | Skydio raised $170M; Artiva landed $120M; FogPharma secured $107M; Axonius picks up $100M
Skydio: Skydio is a Redwood City, Ca.-based autonomous drone-maker. Skydio has raised $170 million in Series D funding at a post-money valuation of mo... |
| 01.03.2021 | 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round | Press Release
4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round
1 March 2021
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused... |
| 01.03.2021 | 4BIO Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced it has become an investor in CARISMA Therapeutics, a biopharmaceutical company focu... |
| 01.03.2021 | CARISMA Therapeutics Completes Series B Financing Totaling $59 Million | |
| 01.03.2021 | IP : CARISMA Therapeutics Inc. - CARISMA Therapeutics Completes Series B Financing Totaling $59 Million | Funds to Support Advancement of Pipeline and Discovery Programs, Including Recently Initiated Phase 1 Trial of Lead Candidate CT-0508
CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative im... |
| 01.03.2021 | IP GROUP PLC
IP : CARISMA Therapeutics Inc. - CARISMA Therapeutics Completes Series B Financing Totaling $59 Million | Funds to Support Advancement of Pipeline and Discovery Programs, Including Recently Initiated Phase 1 Trial of Lead Candidate CT-0508
CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative im... |
| 08.01.2021 | CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies | CARISMA Therapeutics announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital raised to nearly $109 million. |
| 07.01.2021 | CARISMA Therapeutics Lands $47M Series B |
PHILADELPHIA, PA, CARISMA Therapeutics has completed its Series B equity financing providing for gross proceeds of $47 million.
>> Click here for more funding data on CARISMA Therapeutics
>> To export CARISMA Therapeutics fu... |
| 07.01.2021 | CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies | |
| 07.01.2021 | CARISMA Therapeutics Completes $47 Million Series B Funding | CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringi... |
| 07.01.2021 | CARISMA THERAPEUTICS COMPLETES SERIES B FUNDING FOR $47 MILLION TO ADVANCE DEVELOPMENT OF NOVEL CAR-MACROPHAGE IMMUNOTHERAPIES | - |
| 23.03.2020 | Startup Spotlight: Carisma Therapeutics wants to make a cell therapy that will work in solid tumors | When Michael Klichinsky was rotating through University of Pennsylvania hospitals as a pharmacy student more than eight years ago, he asked a lot of cancer specialists a lot of questions — many of which got the same answer.
“Folks that I wa... |
| 14.02.2020 | Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine | In August of 2011, Carl June and his team published a landmark paper showing their CAR–T treatment had cleared a patient of cancer. A year-to-the-month later, Jennifer Doudna made an even bigger splash when she published the fi... |
| 08.08.2019 | Carisma Therapeutics Raised Nearly $60M in Series A Funding. Now What? | Carisma Therapeutics, working on a cellular therapy aimed at fighting solid tumors, is planning for growth: The University City company is hoping to hire about 10 more employees by the end of the year after raising nearly $60 million, its C... |
| 08.08.2019 | Carisma Therapeutics raised nearly $60M in Series A funding. Now what? | Carisma Therapeutics, working on a cellular therapy aimed at fighting solid tumors, is planning for growth: The University City company is hoping to hire about 10 more employees by the end of the year after raising nearly $60 million, its C... |
| 08.08.2019 | Carisma Therapeutics Raised Nearly $60M in Series A Funding. Now What? | Carisma Therapeutics, working on a cellular therapy aimed at fighting solid tumors, is planning for growth: The University City company is hoping to hire about 10 more employees by the end of the year after raising nearly $60 million, its C... |
| 28.06.2018 | Term Sheet — Thursday, June 28 | LYFTED
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Here are some additional notes:
• In total, Lyft has raised $5.1 billion in funding. Lyft’s investors include AllianceBernstein, Baillie... |
| 27.06.2018 | Carisma Therapeutics announces $53 million Series A financing | Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a $53 million Series A financing to further expan... |
| 27.06.2018 | Carisma Therapeutics Raises $53M in Series A Financing | Carisma Therapeutics Inc., formerly known as Carma Therapeutics, a Philadelphia, PA-based biotechnology company focused on the development of macrophage-based immunotherapeutics, closed a $53m Series A financing.
The round was led by AbbVie... |
| 27.06.2018 | Carisma Therapeutics Inc - Announces a $53m Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy |
Carisma Therapeutics Inc
., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a
$53 million
Series A financing to further... |
| 27.06.2018 | Carisma Therapeutics Inks $53M Series A |
PHILADELPHIA, PA, Carisma Therapeutics announced the close of a $53 million Series A financing.
>> Click here for more funding data on Carisma Therapeutics
>> To export Carisma Therapeutics funding data to PDF and Excel, cli... |
| - | Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study | PHILADELPHIA, December 2, 2021 — Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has entered into a clinical study collaboration... |
| - | Carisma Therapeutics | “Carisma Therapeutics is pioneering the development of CAR-Macrophages, a disruptive approach to solid tumor immunotherapy treatment.” |
| - | CARISMA Therapeutics Completes Series B Financing Totaling $59 Million | PHILADELPHIA, March 1, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringi... |
| - | Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology | Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics
Multi-year research collaboration funded by Moderna with options for up to tw... |
| - | CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages | PHILADELPHIA, April 26, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has established a multi-year scientific c... |
| - | First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models | Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors
PHILADELPHIA, March 23, 2020 /PRNewswire/ — Carisma Therapeutics Inc., a biopharmaceutical company focused on discoverin... |
| - | CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies | PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing... |
| - | Carisma Therapeutics to Host Webcast on Phase 1 Clinical Trial of Engineered Macrophage Therapy | PHILADELPHIA, June 17, 2022 /PRNewswire/ — Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will be hosting a webcast on June 24th at 1:00pm ET to present and... |
| - | CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors | PHILADELPHIA, Sept. 22, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that that the U.S. Food and Drug Administrat... |
| - | Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer | PHILADELPHIA, June 3, 2019 /PRNewswire/ — Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on engineered macrophages, today announced Robert Peti... |
| - | Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology | Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics
Multi-year research collaboration funded by Moderna with options for up to tw... |
| - | CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies | Cologne, Germany and Philadelphia, PA, USA February 2, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC) and CARISMA Therapeutics Inc. (CARISMA) today announced the signing of an agreement which grants CARISMA a clinical and commercial license for ... |
| - | Carisma Therapeutics Appoints Sanford Zweifach as Chairman to Board of Directors | PHILADELPHIA, November 29, 2021 – Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Sanford (Sandy) Zweifach has been appointed to the cha... |
| - | Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage | PHILADELPHIA, November 12, 2021, 12:10 PM ET— Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today for the first time preliminary findings fr... |
| - | Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer | – Klichinsky, co-founder of Carisma Therapeutics, co-invented the company’s proprietary and first-of-its-kind engineered macrophage platform
PHILADELPHIA, April 21, 2022 /PRNewswire/ — Carisma Therapeutics Inc., a clinical stage biopharmac... |
| - | Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting | Findings further indicate the potential of engineered macrophages as a new treatment pathway for hard-to-treat cancers and other serious illnesses
Research findings point to feasibility of a shortened manufacturing process for CAR-monocyte... |
| - | CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer | PHILADELPHIA, June 8, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Richard Morris has been appointed Chief F... |
| - | CARISMA Therapeutics Completes Series B Financing Totaling $59 Million | PHILADELPHIA, March 1, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringin... |
| - | Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting | PHILADELPHIA, PA – May 26, 2022 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced two presentations including findings of its lead candidate, ... |
| - | CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans | Clinical trial to study CT-0508 in patients with metastatic HER2 overexpressing solid tumors
PHILADELPHIA, March 18, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company spun out of the University of Pe... |
| - | CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy | PHILADELPHIA, July 27, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared... |
| - | Carisma Therapeutics to Present and Meet with Potential Investors at Upcoming Healthcare Investor Conferences | PHILADELPHIA, May 21, 2020 /PRNewswire/ — Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present and take meetings at upcoming v... |
| - | CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting | – First study evaluating CAR-macrophages in fully immunocompetent solid tumor mouse models shows significant tumor control, increased survival, and induction of anti-tumor immunity
– New ultra-rapid, same-day CAR-monocyte manufacturing pro... |
